Simulations Plus Invests $1 Million in Clinical Trial Technology Company Nurocor
核心洞察
Simulations Plus (搜索) announced a $1 million investment in Nurocor (搜索), a cloud-based clinical development technology company founded in 2017.
The investment is part of Simulations Plus (搜索)' Corporate Development Initiative launched in 2024 to support early-stage pharmaceutical technology companies.
Nurocor (搜索)'s platform aims to accelerate clinical trial lifecycles and reduce development costs through digitalization and automation.
Simulations Plus (搜索), Inc. (Nasdaq: SLP) announced a $1 million investment in clinical development technology company Nurocor (搜索) as part of its Corporate Development Initiative to accelerate pharmaceutical innovation. The investment targets the rapidly growing clinical trial technology sector, which was valued at $25.7 billion in 2024 and is projected to expand at a 15.5% compound annual growth rate through 2030.
Strategic Investment in Clinical Trial Digitalization
Founded in 2017, Nurocor (搜索) operates a cloud-based software platform designed to enhance efficiency, reusability, governance, and automation for pharmaceutical companies during the clinical development phase. The company's solution significantly accelerates the typical clinical trial lifecycle while reducing overall development costs through digitalization.
"We are pleased to support Nurocor (搜索) in its mission to help clients leverage technology to bring drugs to market more rapidly," said Shawn O'Connor, Chief Executive Officer of Simulations Plus (搜索). "Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance."
Corporate Development Initiative Expansion
The investment represents part of Simulations Plus (搜索)' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. Will Frederick, Chief Financial Officer of Simulations Plus, emphasized the strategic nature of the investment.
"This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market," Frederick stated.
Market Growth Drivers
The clinical trial technology and services sector encompasses digital tools and services driven by increasing adoption of digital health technologies and growing demand for more efficient patient recruitment. This market expansion reflects the pharmaceutical industry's push toward more streamlined and cost-effective clinical development processes.
Alex Lazar, Chief Executive Officer of Nurocor (搜索), expressed enthusiasm about the partnership: "We are thrilled to have the support of Simulations Plus (搜索) as we enter our next stage of growth. The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials."
Complementary Technology Solutions
Simulations Plus (搜索), with over 25 years of experience serving global clients, provides advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company's comprehensive biosimulation solutions integrate artificial intelligence/machine learning, physiologically based pharmacokinetics, and population modeling approaches.
O'Connor noted that the investment aligns with the company's mission to deliver measurable value to clients and accelerate the delivery of treatments to patients. The partnership is expected to create synergies between Simulations Plus (搜索)' existing clinical trial capabilities and Nurocor (搜索)'s digitalization platform.